Faes Farma : Q3 earnings a touch below. FY 2023 outlook maintained
>Sales momentum improves slightly while margins post a modest deterioration - Q3 2023 sales reached € 107m (+5% y-o-y vs +3% in Q2 2023, +2% in Q1 2023 and +2% in Q4 2022). By division, sales of traditional products in Spain posted a material sequential improvement and returned to growth territory (+6% y-o-y vs -1% in Q2 2023, -4% in Q1 2023 and -7% in Q4 2022), reflecting higher dynamism in Bilastine (ophthalmic and ODT versions recently launched partially offsetting...Faes Farma is engaged in the health care research, manufacture and sale of prescription pharmaceuticals, over-the-counter pharmaceuticals and fine chemicals, URGO bandages and dressings and LAZLO cosmetics.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.